Selecting patients with ‘sufficient life expectancy’ for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ⩾2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback